---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-113410"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2024-10-08T23:59:59+00:00"
generated_at: "2026-05-30T18:15:21.177372+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PepGen reports favorable safety profile for PGN-EDO51 in Phase 2 DMD trial at WMS Congress

## Summary
- CONNECT1-EDO51 safety data as of Oct 3: no serious adverse events; all treatment-related AEs mild and resolved.
- One hypomagnesemia case resolved with oral supplementation; no discontinuations, dose interruptions or reductions.
- Presenting short oral and five posters on PGN-EDO51 (DMD) and PGN-EDODM1 (DM1) at WMS Congress in Prague Oct 8-12.
- Nonclinical data for both programs and FREEDOM-DM1 trial design also featured in poster sessions.

## SEC filing metadata
- accession: 0000950170-24-113410
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2024-10-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000095017024113410/0000950170-24-113410-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000095017024113410/pepg-20241008.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-113410
- JSON: https://secwatch.observer/filing/0000950170-24-113410.json
- Plain text: https://secwatch.observer/filing/0000950170-24-113410.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.